Krebs board approves merger with Ipca Labs; share swap 7 Ipca shares per 200 Krebs shares

Board approved scheme of amalgamation of Krebs Biochemicals with Ipca Laboratories under Sections 230-232 of the Companies Act, 2013. Appointed date is April 1, 2026. No cash consideration; share swap ratio is 7 fully paid Ipca equity shares (Re.1 each) for every 200 fully paid Krebs shares (Rs.10 each). Ipca FY26 total income was Rs.7,431 Cr while Krebs FY26 income was Rs.26 Cr, mostly from conversion charges from Ipca. Both are in pharma manufacturing. Rationale includes operational synergies and Krebs bringing fermentation based API capability that Ipca lacks. Treated as related party transaction at arms length. Subject to NCLT, SEBI and other approvals.